Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.49 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3319291 | 0.88 | MKNK1 (0.52) | MKNK1MKNK2RAB9AKDM4EMAPT | |
| SCHEMBL3553616 | 0.87 | MKNK1 (0.47) | MKNK1MKNK2MAPTKLK7CYP19A1 | |
| SCHEMBL3560389 | 0.87 | MCL1 (0.52) | MCL1RAB9AMAPTNPC1LMNA | |
| Hydrochloric Acid SCHEMBL3319623 | 0.87 | MKNK1 (0.51) | MKNK1MKNK2RAB9AKDM4EMAPT | |
| SCHEMBL3098576 | 0.87 | MKNK1 (0.48) | MKNK1MKNK2MCL1MAPTKLK7 | |
| SCHEMBL13335837 | 0.85 | MKNK1 (0.45) | MKNK1MKNK2KDM4EMAPTKLK7 | |
| SCHEMBL3102308 | 0.85 | MCL1 (0.50) | MCL1RAB9AMAPTNPC1LMNA | |
| SCHEMBL3092548 | 0.83 | MCL1 (0.48) | MCL1RAB9AKDM4EMAPTNPC1 | |
| SCHEMBL3550452 | 0.83 | MCL1 (0.52) | MCL1RAB9AKDM4EMAPTNPC1 | |
| SCHEMBL3556744 | 0.82 | MCL1 (0.47) | MCL1RAB9AMAPTNPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659412-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER HEALTHCARE LLC (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090023783-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | ZHANG CHENGZHI | 2009-01-22 | — | — | US | disclosed |
| US-7420066-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-20060194816-A1 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAER PHAMACEUTICALS CORPORATION (US) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194816-A1 | Benzofuran derivatives useful for treating hyper-proliferative disorders | MKI67, PCNA, CCNI | MKNK1 1953/4885MKNK2 2039/4885MCL1 55/4885 |
| US-20090023783-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | PCNA, MKI67, CDK4 | MKNK1 2068/4885MKNK2 2279/4885MCL1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.